Description

Immunohistochemistry staining of prostate cancer xenograft tissue sections for CES1 expression and lipid metabolism markers following melatonin treatment.

Figure 21

Micrograph

Source Paper

Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.

Clinical and translational medicine (2021)

PMID: 34185414

DOI: 10.1002/ctm2.449

Cite This Figure

![Figure 21: Immunohistochemistry staining of prostate cancer xenograft tissue sections for CES1 expression and lipid metabolism markers following melatonin treatment.]()

> Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." *Clinical and translational medicine*, 2021. PMID: [34185414](https://pubmed.ncbi.nlm.nih.gov/34185414/)

<figure>
  <img src="" alt="Immunohistochemistry staining of prostate cancer xenograft tissue sections for CES1 expression and lipid metabolism markers following melatonin treatment." />
  <figcaption>Figure 21. Immunohistochemistry staining of prostate cancer xenograft tissue sections for CES1 expression and lipid metabolism markers following melatonin treatment.<br>  Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." <em>Clinical and translational medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34185414/">34185414</a></figcaption>
</figure>

Preuves associées

Mélatonine pour Trouble du Rythme Circadien

Note A · 176 études